Golidocitinib plus selinexor for chronic active Epstein‑Barr virus disease (CAEBVD)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, prospective, single‑arm Phase 2/3 trial gives adults with CAEBVD a combined regimen of golidocitinib and selinexor and follows them to measure response and safety. Eligible patients must meet the 2025 diagnostic consensus for CAEBVD and have ECOG 0–1 and acceptable liver, kidney, blood, and coagulation tests. All enrolled participants receive the combination therapy and undergo regular clinical assessments, laboratory monitoring, and imaging as specified in the protocol. Primary endpoints focus on disease response and tolerability, with secondary endpoints including duration of response and progression to further therapies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. CAEBVD diagnosed in accordance with the Consensus on the Diagnosis and Treatment of Chronic Active Epstein-Barr Virus Disease (2025 Edition).
2. Aged ≥ 18 years and ≤ 70 years, regardless of gender.
3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
4. Before the initiation of the study, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN); total bilirubin ≤ 2 × ULN; serum creatinine ≤ 1.5 × ULN.
5. Routine blood test: absolute neutrophil count ≥ 1 × 10#/L; platelet count ≥ 50 × 10#/L; hemoglobin ≥ 60 g/L.
6. Coagulation function test requirements: international normalized ratio (INR) ≤ 2.0; prothrombin time (PT) ≤ 1.5 × ULN.
7. Women of childbearing potential must have a negative pregnancy test result, and be willing to take effective contraceptive measures during the trial period and for ≥ 12 months after the last dose; all male subjects must take contraceptive measures during the trial period and for ≥ 6 months after the last dose.
8. Signed informed consent form.

Exclusion Criteria:

1. Evidence of EBV-associated hematological diseases or malignancies, such as hemophagocytic lymphohistiocytosis, lymphomatoid granulomatosis, post-transplant lymphoproliferative disorder, non-Hodgkin's lymphoma, Burkitt lymphoma, nasopharyngeal carcinoma, and gastric cancer.
2. Having received any of the following treatments: prior treatment with any JAK inhibitor; administration of any investigational drug within 12 weeks prior to the first dose of the study drug; concurrent enrollment in another clinical study.
3. A history of other primary malignancies within 5 years prior to the first dose of the study drug, excluding locally curable malignancies that have received curative treatment (e.g., basal or squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast).
4. A history of organ transplantation (e.g., liver transplantation, kidney transplantation).
5. Planned hematopoietic stem cell transplantation during the study period.
6. Active hepatitis B (defined as positive hepatitis B surface antigen \[HBsAg\] at screening, or a peripheral blood hepatitis B virus DNA titer \> 1×10³ copies/mL); active hepatitis C (defined as positive anti-hepatitis C virus antibody \[HCV-Ab\] and HCV-RNA at screening); positive serum HIV antigen or antibody; a history of syphilis.
7. Having undergone major surgery within 4 weeks prior to the first dose, or anticipating the need for major surgery during the study period.
8. Pregnant or lactating women.
9. A history of severe mental illness or drug abuse.
10. Uncontrolled infections (including pulmonary infection, intestinal infection); active major visceral hemorrhage (including gastrointestinal bleeding, alveolar hemorrhage, intracranial hemorrhage).
11. Hypersensitivity to the components of the study drug, or a history of severe allergic diathesis.
12. Patients who are unable to comply with the requirements during the trial and/or follow-up phase.

Where it's running

• Beijing Friendship Hospital
  Beijing, China Recruiting

Study contacts

• Study coordinator: Jingshi Wang
• Email: wangjingshi987@126.com
• Phone: 86-010-80838351

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Golidocitinib and chidamide for cutaneous T-cell lymphoma

  This study tests whether the combo of golidocitinib and chidamide helps people with CTCL that has already received prior systemic therapy.

  Recruiting Phase 1/2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07754890

• mRNA EBV vaccine in healthy young adults

  A first-in-human, dose-escalation study will test an mRNA vaccine (VXCO-102) to see if it is safe and can provoke an immune response in healthy 18–25 year olds.

  Recruiting at 2 sites Phase 1 Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company · Herston, Queensland and 1 other locations · NCT07557602

• MEPL-G combination therapy for NK/T‑cell lymphoma with HLH

  This trial will test whether the MEPL-G drug combination (liposomal mitoxantrone, etoposide, pegaspargase, methylprednisolone, and golidocitinib) can control both the lymphoma and the life‑threatening HLH inflammation in adults with NK/T‑cell lymphoma–associated HLH.

  Recruiting Phase 1/2 Beijing Tongren Hospital · Beijing · NCT07525466

• GW5282 with golidocitinib versus CHOP for peripheral T‑cell lymphoma

  This will test whether combining GW5282 with golidocitinib helps adults with peripheral T‑cell lymphoma more than standard CHOP chemotherapy.

  Recruiting Phase 1/2 Dizal Pharmaceuticals · Chongqing, Chongqing Municipality and 11 other locations · NCT07496229

• Golidocitinib versus placebo as maintenance treatment for PTCL patients in remission after first-line chemotherapy

  This trial tests whether taking golidocitinib every other day can help keep peripheral T‑cell lymphoma from coming back in adults who responded to first‑line chemotherapy but cannot have a stem cell transplant.

  Recruiting Phase 3 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT07414758

• Golidocitinib (GO) treatment for hemophagocytic lymphohistiocytosis

  This trial will test whether the oral drug golidocitinib (GO) can safely treat people aged 14–70 with newly diagnosed or relapsed/refractory hemophagocytic lymphohistiocytosis who are not candidates for stem cell transplant.

  Recruiting Phase 2/3 Beijing Friendship Hospital · Beijing, Beijing Municipality · NCT07339345

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.